161 related articles for article (PubMed ID: 27181389)
1. Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
Dai D; Thiel KW; Salinas EA; Goodheart MJ; Leslie KK; Gonzalez Bosquet J
Gynecol Oncol; 2016 Jul; 142(1):150-157. PubMed ID: 27181389
[TBL] [Abstract][Full Text] [Related]
2. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
3. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
5. Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort.
Verbakel JY; Mascilini F; Wynants L; Fischerova D; Testa AC; Franchi D; Frühauf F; Cibula D; Lindqvist PG; Fruscio R; Haak LA; Opolskiene G; Alcazar JL; Mais V; Carlson JW; Sladkevicius P; Timmerman D; Valentin L; Bosch TVD; Epstein E
Ultrasound Obstet Gynecol; 2020 Jan; 55(1):115-124. PubMed ID: 31225683
[TBL] [Abstract][Full Text] [Related]
6. The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.
Atguden Z; Yildiz A; Aksut H; Yalcin SE; Yalcin Y; Uysal D; Yetimalar H
Asian Pac J Cancer Prev; 2016; 17(2):497-501. PubMed ID: 26925634
[TBL] [Abstract][Full Text] [Related]
7. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
8. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
9. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
14. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
15. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
17. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
18. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
19. Pathological characteristics and risk stratification in patients with stage I endometrial cancer: utility of apparent diffusion coefficient histogram analysis.
An T; Kim CK
Br J Radiol; 2021 Oct; 94(1126):20210151. PubMed ID: 34233478
[TBL] [Abstract][Full Text] [Related]
20. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
Zighelboim I; Schmidt AP; Gao F; Thaker PH; Powell MA; Rader JS; Gibb RK; Mutch DG; Goodfellow PJ
J Clin Oncol; 2009 Jul; 27(19):3091-6. PubMed ID: 19470935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
